Early access
Sign in
CompletedPhase 2

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

Key facts

Who runs it
SWOG Cancer Research Network
Where
Aberdeen, Anaconda, Anchorage, Arroyo Grande, Baker City, Baltimore, Bardstown, Bellevue, Bellingham, Bend, Billings, Boise, Bozeman, Bremerton, Brownstown, Bryan, Burbank, Burien, Burnsville, Caldwell, Cambridge, Carson City, Centralia, Chattanooga, Chicago, Chippewa Falls, Cincinnati, Clackamas, Clinton Township, Clive, Cody, Coeur d'Alene, Colorado Springs, Coon Rapids, Coos Bay, Corbin, Council Bluffs, Creston, Dearborn, Denver, Des Moines, Detroit, Duarte, Durango, Easley, Eau Claire, Edina, Edmonds, Emmett, Enumclaw, Everett, Federal Way, Fridley, Fruitland, Golden, Grand Island, Great Falls, Greenville, Greer, Harrisburg, Helena, Henderson, Hixson, Hot Springs, Houston, Issaquah, Jackson, Kalispell, Kearney, Kennewick, Kingman, Lacey, Ladysmith, Lake Forest, Lakewood, Lancaster, Las Vegas, Lexington, Lincoln, Littleton, London, Longmont, Longview, Louisville, Maple Grove, Maplewood, Marshfield, Marysville, Meridian, Minneapolis, Minocqua, Mission Hills, Missoula, Monticello, Nampa, New Richmond, New Ulm, New York, Newberg, Novi, Omaha, Ontario, Ooltewah, Pahrump, Papillion, Parker, Philadelphia, Pittsburgh, Portland, Post Falls, Poulsbo, Princeton, Pueblo, Redmond, Reno, Renton, Rice Lake, Robbinsdale, Sacramento, Saint Louis Park, Saint Paul, Salt Lake City, Sandpoint, Santa Maria, Seattle, Sedro-Woolley, Seneca, Shakopee, Shelby, Shelton, Shepherdsville, Sheridan, South Pasadena, Spartanburg, Stevens Point, Stillwater, Syracuse, Tacoma, Tampa, Thornton, Twin Falls, Vancouver, Waconia, Walla Walla, Wausau, West Bloomfield, West Covina, West Des Moines, Weston, Willmar, Wisconsin Rapids, Woodbury, Wyoming, and Yelm, United StatesSee the 254 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
21 people enrolled
Started
20 Mar 2019
Ended
3 Mar 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Carboplatin
  • Paclitaxel
  • Ramucirumab
Record updated
30 October 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 33 criteriaShow less

Who can take part

  • Patients must have histologically or cytologically confirmed thymic carcinoma; thymic carcinoma may be defined as "thymic epithelial malignancy, consistent with thymic carcinoma", or "World Health Organization (WHO) type C thymic epithelial tumor", or "thymic epithelial malignancy" with radiographic imaging consistent with thymic carcinoma
  • Patients must have unresectable thymic carcinoma, that is either locally advanced, recurrent, or metastatic
  • Patients must not be candidates for localized surgery
  • Patients must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI) within 28 calendar days prior to randomization; the CT from a combined positron emission tomography (PET)/CT may be used only if it is of diagnostic quality; non-measurable disease must be assessed within 42 calendar days prior to randomization; all known sites of disease must be assessed and documented on the baseline tumor assessment form (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
  • Patients must have a Zubrod performance status of 0 to 2
  • Patients must not have undergone major surgery within 28 calendar days prior to randomization, or minor surgery/subcutaneous venous access device placement within 7 calendar days prior to randomization; the patient must not have elective or planned major surgery to be performed during the course of the clinical trial
  • Patients must not have had prior systemic anti-cancer therapy for locally advanced or metastatic unresectable thymic carcinoma
  • If patients have recurrent unresectable thymic carcinoma, patients may have had prior neoadjuvant or adjuvant chemotherapy if treatment concluded >= 6 months prior to randomization
  • Patients must have a CT or MRI scan of the brain to evaluate for central nervous system (CNS) disease within 42 calendar days prior to registration; patient must not have brain metastases unless: (1) metastases have been treated and have remained controlled for at least two weeks following treatment, AND (2) patient has no residual neurological dysfunction off corticosteroids for at least 1 day
  • Patients must not be candidates for radiation therapy with curative intent; prior palliative radiation therapy is allowed as long as a period of 7 days has passed since the last dose was received and the patient has recovered from any associated toxicity at the time of randomization
  • Absolute neutrophil count (ANC) >= 1500/mcL documented within 28 calendar days prior to randomization
  • Hemoglobin >= 9 g/dL (5.58 mmol/L) documented within 28 calendar days prior to randomization
  • Platelets >= 100,000/mcL documented within 28 calendar days prior to randomization
  • International normalized ratio (INR) =< 1.5 documented within 28 calendar days prior to randomization
  • Partial thromboplastin time (PTT) =< 5 seconds above the institutional upper limit of normal (IULN) (unless receiving anticoagulation therapy) documented within 28 calendar days prior to randomization
  • Patients receiving warfarin must be switched to low molecular weight heparin and have achieved stable coagulation profile 14 days prior to randomization
  • Patients must not have experienced any grade 3 or above gastrointestinal (GI) bleeding within 84 calendar days prior to randomization
  • Patients must not have a history of deep vein thrombosis (DVT), pulmonary embolism (PE), or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered "significant") during the 84 calendar days prior to randomization
  • Total bilirubin =< 1.5 x the institutional upper limit normal (IULN) documented within 28 calendar days prior to randomization
  • Aspartate aminotransferase (aspartate transaminase [AST]) and alanine aminotransferase (alanine transaminase [ALT]) =< 3.0 x IULN; for patients with liver metastases, total bilirubin and AST or ALT must be =< 5.0 x IULN documented within 28 calendar days prior to randomization
  • Patients must not have any of following:; Cirrhosis at a level of Child-Pugh B (or worse); Cirrhosis (any degree) and a history of hepatic encephalopathy; or; Clinically meaningful ascites resulting from cirrhosis; clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis
  • Serum creatinine =< 1.5 x IULN, or creatinine clearance (measured via 24-hour urine collection) >= 40 mL/minute (that is, if serum creatinine is > 1.5 x ULN, a 24-hour urine collection to calculate creatinine clearance must be performed) documented within 28 calendar days prior to randomization
  • Patient urinary protein must be =< 1+ on dipstick or routine urinalysis (UA); if urine dipstick or routine analysis is >= 2+, a 24-hour urine collection for protein must demonstrate < 1000 mg of protein in 24 hours); these tests must be documented within 28 calendar days prior to randomization
  • Patients must not have experienced any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, within 6 months prior to randomization
  • Patients must not have a history of uncontrolled or poorly-controlled hypertension (defined as > 160 mmHg systolic or > 100 mmHg diastolic for > 4 weeks) despite standard medical management
  • Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method (hormonal or barrier method of birth control; abstinence) prior to randomization, during the study participation and for 4 months after the last dose of protocol treatment; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
  • Patients must not have experienced hemoptysis (defined as bright red blood or >= 1/2 teaspoon) within 2 months prior to randomization or with radiographic evidence of intratumor cavitation or has radiologically documented evidence of major blood vessel invasion or encasement by cancer
  • Patients must not have a prior history of gastrointestinal perforation/fistula (within 6 months of randomization) or risk factors for perforation
  • Patients must not have a serious or nonhealing wound, ulcer, or bone fracture within 28 calendar days prior to randomization
  • Patients must not be receiving chronic antiplatelet therapy, including aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs, including ibuprofen, naproxen, and others), dipyridamole or clopidogrel, or similar agents within 7 days prior to randomization; once-daily aspirin use (maximum dose 325 mg/day) is permitted
  • Patients must be offered the opportunity to participate in banking of specimens for future research
  • Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
  • As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system

Where in United States

  • Providence Regional Cancer System-AberdeenAberdeen, United States
  • Community Hospital of AnacondaAnaconda, United States
  • Alaska Breast Care and Surgery LLCAnchorage, United States
  • Alaska Oncology and Hematology LLCAnchorage, United States
  • Alaska Women's Cancer CareAnchorage, United States
  • Anchorage Associates in Radiation MedicineAnchorage, United States
  • Anchorage Oncology CentreAnchorage, United States
  • Anchorage Radiation Therapy CenterAnchorage, United States
  • Katmai Oncology GroupAnchorage, United States
  • Providence Alaska Medical CenterAnchorage, United States
  • Mission Hope Medical Oncology - Arroyo GrandeArroyo Grande, United States
  • PCR OncologyArroyo Grande, United States
  • Saint Alphonsus Medical Center-Baker CityBaker City, United States
  • Greater Baltimore Medical CenterBaltimore, United States
  • Flaget Memorial HospitalBardstown, United States
  • Overlake Medical CenterBellevue, United States
  • PeaceHealth Saint Joseph Medical CenterBellingham, United States
  • Saint Charles Health SystemBend, United States
  • Billings Clinic Cancer CenterBillings, United States
  • Saint Alphonsus Cancer Care Center-BoiseBoise, United States
  • Saint Luke's Mountain States Tumor InstituteBoise, United States
  • Bozeman Deaconess HospitalBozeman, United States
  • Harrison HealthPartners Hematology and Oncology-BremertonBremerton, United States
  • Harrison Medical CenterBremerton, United States
  • Henry Ford Cancer Institute-DownriverBrownstown, United States
  • Saint Joseph Regional Cancer CenterBryan, United States
  • Providence Saint Joseph Medical Center/Disney Family Cancer CenterBurbank, United States
  • Highline Medical Center-Main CampusBurien, United States
  • Fairview Ridges HospitalBurnsville, United States
  • Minnesota Oncology - BurnsvilleBurnsville, United States
  • Saint Alphonsus Cancer Care Center-CaldwellCaldwell, United States
  • Cambridge Medical CenterCambridge, United States
  • Carson Tahoe Regional Medical CenterCarson City, United States
  • Providence Regional Cancer System-CentraliaCentralia, United States
  • Memorial HospitalChattanooga, United States
  • Northwestern UniversityChicago, United States
  • Marshfield Clinic-Chippewa CenterChippewa Falls, United States
  • Bethesda North HospitalCincinnati, United States
  • Good Samaritan Hospital - CincinnatiCincinnati, United States
  • TriHealth Cancer Institute-AndersonCincinnati, United States
  • TriHealth Cancer Institute-WestsideCincinnati, United States
  • Clackamas Radiation Oncology CenterClackamas, United States
  • Providence Cancer Institute Clackamas ClinicClackamas, United States
  • Henry Ford Macomb Hospital-Clinton TownshipClinton Township, United States
  • Medical Oncology and Hematology Associates-West Des MoinesClive, United States
  • Mercy Cancer Center-West LakesClive, United States
  • Billings Clinic-CodyCody, United States
  • Kootenai Medical CenterCoeur d'Alene, United States
  • Penrose-Saint Francis HealthcareColorado Springs, United States
  • Rocky Mountain Cancer Centers-PenroseColorado Springs, United States
  • Mercy HospitalCoon Rapids, United States
  • Bay Area HospitalCoos Bay, United States
  • Commonwealth Cancer Center-CorbinCorbin, United States
  • Alegent Health Mercy HospitalCouncil Bluffs, United States
  • Greater Regional Medical CenterCreston, United States
  • Henry Ford Medical Center-FairlaneDearborn, United States
  • Porter Adventist HospitalDenver, United States
  • Medical Oncology and Hematology Associates-LaurelDes Moines, United States
  • Mercy Medical Center - Des MoinesDes Moines, United States
  • Henry Ford HospitalDetroit, United States
  • City of Hope Comprehensive Cancer CenterDuarte, United States
  • Mercy Medical CenterDurango, United States
  • Southwest Oncology PCDurango, United States
  • Prisma Health Cancer Institute - EasleyEasley, United States
  • Marshfield Medical Center-EC Cancer CenterEau Claire, United States
  • Fairview Southdale HospitalEdina, United States
  • Swedish Cancer Institute-EdmondsEdmonds, United States
  • Walter Knox Memorial HospitalEmmett, United States
  • Saint Elizabeth HospitalEnumclaw, United States
  • Providence Regional Cancer PartnershipEverett, United States
  • Saint Francis HospitalFederal Way, United States
  • Unity HospitalFridley, United States
  • Saint Luke's Cancer Institute - FruitlandFruitland, United States
  • Mountain Blue Cancer Care CenterGolden, United States
  • CHI Health Saint FrancisGrand Island, United States
  • Benefis Healthcare- Sletten Cancer InstituteGreat Falls, United States
  • Great Falls ClinicGreat Falls, United States
  • Prisma Health Cancer Institute - ButternutGreenville, United States
  • Prisma Health Cancer Institute - EastsideGreenville, United States
  • Prisma Health Cancer Institute - FarisGreenville, United States
  • Prisma Health Cancer Institute - GreerGreer, United States
  • UPMC Pinnacle Cancer Center/Community Osteopathic CampusHarrisburg, United States
  • Saint Peter's Community HospitalHelena, United States
  • 21st Century Oncology-HendersonHenderson, United States
  • Cancer and Blood Specialists-HendersonHenderson, United States
  • Comprehensive Cancer Centers of Nevada - HendersonHenderson, United States
  • Comprehensive Cancer Centers of Nevada-Horizon RidgeHenderson, United States
  • Comprehensive Cancer Centers of Nevada-Southeast HendersonHenderson, United States
  • Las Vegas Cancer Center-HendersonHenderson, United States
  • Las Vegas Urology - Green ValleyHenderson, United States
  • Las Vegas Urology - PebbleHenderson, United States
  • OptumCare Cancer Care at Seven HillsHenderson, United States
  • Urology Specialists of Nevada - Green ValleyHenderson, United States
  • Pulmonary Medicine Center of Chattanooga-HixsonHixson, United States
  • CHI Saint Vincent Cancer Center Hot SpringsHot Springs, United States
  • M D Anderson Cancer CenterHouston, United States
  • Swedish Cancer Institute-IssaquahIssaquah, United States
  • Allegiance HealthJackson, United States
  • University of Mississippi Medical CenterJackson, United States
  • Kalispell Regional Medical CenterKalispell, United States
  • CHI Health Good SamaritanKearney, United States
  • Heartland Hematology and OncologyKearney, United States
  • Kadlec Clinic Hematology and OncologyKennewick, United States
  • Kingman Regional Medical CenterKingman, United States
  • Providence Regional Cancer System-LaceyLacey, United States
  • Marshfield Clinic - Ladysmith CenterLadysmith, United States
  • Northwestern Medicine Lake Forest HospitalLake Forest, United States
  • Rocky Mountain Cancer Centers-LakewoodLakewood, United States
  • Saint Anthony HospitalLakewood, United States
  • Saint Clare HospitalLakewood, United States
  • City of Hope Antelope ValleyLancaster, United States
  • 21st Century OncologyLas Vegas, United States
  • 21st Century Oncology-Fort ApacheLas Vegas, United States
  • 21st Century Oncology-Vegas TenayaLas Vegas, United States
  • Alliance for Childhood Diseases/Cure 4 the Kids FoundationLas Vegas, United States
  • Ann M Wierman MD LTDLas Vegas, United States
  • Cancer and Blood Specialists-ShadowLas Vegas, United States
  • Cancer and Blood Specialists-TenayaLas Vegas, United States
  • Comprehensive Cancer Centers of NevadaLas Vegas, United States
  • Comprehensive Cancer Centers of Nevada - Central ValleyLas Vegas, United States
  • Comprehensive Cancer Centers of Nevada - NorthwestLas Vegas, United States
  • Comprehensive Cancer Centers of Nevada - Town CenterLas Vegas, United States
  • Comprehensive Cancer Centers of Nevada-SummerlinLas Vegas, United States
  • Desert West SurgeryLas Vegas, United States
  • HealthCare Partners Medical Group Oncology/Hematology-Centennial HillsLas Vegas, United States
  • HealthCare Partners Medical Group Oncology/Hematology-Maryland ParkwayLas Vegas, United States
  • HealthCare Partners Medical Group Oncology/Hematology-San MartinLas Vegas, United States
  • HealthCare Partners Medical Group Oncology/Hematology-TenayaLas Vegas, United States
  • Hope Cancer Care of NevadaLas Vegas, United States
  • Las Vegas Cancer Center-Medical CenterLas Vegas, United States
  • Las Vegas Prostate Cancer CenterLas Vegas, United States
  • Las Vegas Urology - Cathedral RockLas Vegas, United States
  • Las Vegas Urology - PecosLas Vegas, United States
  • Las Vegas Urology - Smoke RanchLas Vegas, United States
  • Las Vegas Urology - SunsetLas Vegas, United States
  • OptumCare Cancer Care at Fort ApacheLas Vegas, United States
  • OptumCare Cancer Care at MountainViewLas Vegas, United States
  • OptumCare Cancer Care at OakeyLas Vegas, United States
  • Radiation Oncology Centers of Nevada CentralLas Vegas, United States
  • Radiation Oncology Centers of Nevada SoutheastLas Vegas, United States
  • Summerlin Hospital Medical CenterLas Vegas, United States
  • Sunrise Hospital and Medical CenterLas Vegas, United States
  • University Cancer CenterLas Vegas, United States
  • University Medical Center of Southern NevadaLas Vegas, United States
  • Urology Specialists of Nevada - CentralLas Vegas, United States
  • Urology Specialists of Nevada - NorthwestLas Vegas, United States
  • Urology Specialists of Nevada - SouthwestLas Vegas, United States
  • Saint Joseph Hospital EastLexington, United States
  • Saint Joseph Radiation Oncology Resource CenterLexington, United States
  • Saint Elizabeth Regional Medical CenterLincoln, United States
  • Littleton Adventist HospitalLittleton, United States
  • Saint Joseph LondonLondon, United States
  • Longmont United HospitalLongmont, United States
  • Rocky Mountain Cancer Centers-LongmontLongmont, United States
  • PeaceHealth Saint John Medical CenterLongview, United States
  • Jewish HospitalLouisville, United States
  • Jewish Hospital Medical Center NortheastLouisville, United States
  • Saints Mary and Elizabeth HospitalLouisville, United States
  • Fairview Clinics and Surgery Center Maple GroveMaple Grove, United States
  • Minnesota Oncology Hematology PA-MaplewoodMaplewood, United States
  • Saint John's Hospital - HealtheastMaplewood, United States
  • Marshfield Medical Center-MarshfieldMarshfield, United States
  • Fremont - Rideout Cancer CenterMarysville, United States
  • Idaho Urologic Institute-MeridianMeridian, United States
  • Saint Luke's Cancer Institute - MeridianMeridian, United States
  • Abbott-Northwestern HospitalMinneapolis, United States
  • Health Partners IncMinneapolis, United States
  • Hennepin County Medical CenterMinneapolis, United States
  • Marshfield Clinic-Minocqua CenterMinocqua, United States
  • City of Hope Mission HillsMission Hills, United States
  • Community Medical HospitalMissoula, United States
  • Saint Patrick Hospital - Community HospitalMissoula, United States
  • Monticello Cancer CenterMonticello, United States
  • Saint Alphonsus Medical Center-NampaNampa, United States
  • Saint Luke's Cancer Institute - NampaNampa, United States
  • Cancer Center of Western WisconsinNew Richmond, United States
  • New Ulm Medical CenterNew Ulm, United States
  • NYP/Weill Cornell Medical CenterNew York, United States
  • Providence Newberg Medical CenterNewberg, United States
  • Henry Ford Medical Center-ColumbusNovi, United States
  • Alegent Health Bergan Mercy Medical CenterOmaha, United States
  • Alegent Health Immanuel Medical CenterOmaha, United States
  • Alegent Health Lakeside HospitalOmaha, United States
  • Creighton University Medical CenterOmaha, United States
  • Hematology and Oncology Consultants PCOmaha, United States
  • Saint Alphonsus Medical Center-OntarioOntario, United States
  • Memorial GYN PlusOoltewah, United States
  • Hope Cancer Care of Nevada-PahrumpPahrump, United States
  • Midlands Community HospitalPapillion, United States
  • Parker Adventist HospitalParker, United States
  • Rocky Mountain Cancer Centers-ParkerParker, United States
  • Fox Chase Cancer CenterPhiladelphia, United States
  • University of Pittsburgh Cancer Institute (UPCI)Pittsburgh, United States
  • Providence Portland Medical CenterPortland, United States
  • Providence Saint Vincent Medical CenterPortland, United States
  • Kootenai Cancer CenterPost Falls, United States
  • Harrison HealthPartners Hematology and Oncology-PoulsboPoulsbo, United States
  • Fairview Northland Medical CenterPrinceton, United States
  • Rocky Mountain Cancer Centers - PuebloPueblo, United States
  • Saint Mary Corwin Medical CenterPueblo, United States
  • Saint Charles Health System-RedmondRedmond, United States
  • Radiation Oncology AssociatesReno, United States
  • Renown Regional Medical CenterReno, United States
  • Saint Mary's Regional Medical CenterReno, United States
  • Valley Medical CenterRenton, United States
  • Marshfield Medical Center-Rice LakeRice Lake, United States
  • North Memorial Medical Health CenterRobbinsdale, United States
  • University of California Davis Comprehensive Cancer CenterSacramento, United States
  • Park Nicollet Clinic - Saint Louis ParkSaint Louis Park, United States
  • Regions HospitalSaint Paul, United States
  • United HospitalSaint Paul, United States
  • Huntsman Cancer Institute/University of UtahSalt Lake City, United States
  • Kootenai Cancer ClinicSandpoint, United States
  • Mission Hope Medical Oncology - Santa MariaSanta Maria, United States
  • Fred Hutchinson Cancer Research CenterSeattle, United States
  • Kaiser Permanente WashingtonSeattle, United States
  • Pacific Gynecology SpecialistsSeattle, United States
  • Seattle Cancer Care AllianceSeattle, United States
  • Swedish Medical Center-Ballard CampusSeattle, United States
  • Swedish Medical Center-Cherry HillSeattle, United States
  • Swedish Medical Center-First HillSeattle, United States
  • University of Washington Medical CenterSeattle, United States
  • PeaceHealth United General Medical CenterSedro-Woolley, United States
  • Prisma Health Cancer Institute - SenecaSeneca, United States
  • Saint Francis Regional Medical CenterShakopee, United States
  • Henry Ford Macomb Health Center - Shelby TownshipShelby, United States
  • Providence Regional Cancer System-SheltonShelton, United States
  • Jewish Hospital Medical Center SouthShepherdsville, United States
  • Welch Cancer CenterSheridan, United States
  • City of Hope South PasadenaSouth Pasadena, United States
  • Prisma Health Cancer Institute - SpartanburgSpartanburg, United States
  • Marshfield Clinic Stevens Point CenterStevens Point, United States
  • Lakeview HospitalStillwater, United States
  • State University of New York Upstate Medical UniversitySyracuse, United States
  • Franciscan Research Center-Northwest Medical PlazaTacoma, United States
  • Northwest Medical Specialties PLLCTacoma, United States
  • Moffitt Cancer CenterTampa, United States
  • Moffitt Cancer Center - McKinley CampusTampa, United States
  • Moffitt Cancer Center-International PlazaTampa, United States
  • Rocky Mountain Cancer Centers-ThorntonThornton, United States
  • Saint Luke's Cancer Institute - Twin FallsTwin Falls, United States
  • PeaceHealth Southwest Medical CenterVancouver, United States
  • Ridgeview Medical CenterWaconia, United States
  • Providence Saint Mary Regional Cancer CenterWalla Walla, United States
  • Marshfield Clinic-Wausau CenterWausau, United States
  • Henry Ford West Bloomfield HospitalWest Bloomfield, United States
  • City of Hope West CovinaWest Covina, United States
  • Mercy Medical Center-West LakesWest Des Moines, United States
  • Marshfield Clinic - Weston CenterWeston, United States
  • Rice Memorial HospitalWillmar, United States
  • Marshfield Clinic - Wisconsin Rapids CenterWisconsin Rapids, United States
  • Minnesota Oncology Hematology PA-WoodburyWoodbury, United States
  • Fairview Lakes Medical CenterWyoming, United States
  • Providence Regional Cancer System-YelmYelm, United States

About the trial

What the trial wants to find out

This randomized phase II trial studies how well carboplatin and paclitaxel with or without ramucirumab work in treating patients with thymic cancer that has spread to other places in the body, has come back, or cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as ramucirumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known if giving carboplatin and paclitaxel with or without ramucirumab will work better in treating patients with thymic cancer.

The 2 groups in the trial

  • Arm A (ramucirumab, carboplatin, paclitaxel)Treatment being tested

    Patients receive ramucirumab IV over 60 minutes, carboplatin IV, and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have not progressed may continue to receive ramucirumab for up to 1 year.

    Treatment: Carboplatin, Paclitaxel, and Ramucirumab

  • Arm B (carboplatin, paclitaxel)Existing treatment, for comparison

    Patients receive carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.

    Treatment: Carboplatin and Paclitaxel

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
Record updated
30 October 2025